Janssen-Cilag International NV, a subsidiary of Johnson & Johnson Co. (JNJ), Friday announced that the European Commission has approved a Type II variation for Rybrevant in combination with chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
The company said that the approval was based on results from the Phase 3 Papillon study, which demonstrated that Rybrevant plus chemotherapy reduced the risk of disease progression or death by 60 percent compared to chemotherapy alone.
Following the approval, the conditional marketing authorisation for Rybrevant has been changed to a standard marketing authorisation.
Currently, Johnson & Johnson's stock is trading at $146.20, up 0.27 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.